GlassScriptPhysician profile
Samantha E Myers
NPI 1023504974
$4,363.09
in general payments reported to CMS, 2019-2025
17 companies · $573 in 2025
The $573 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,700 · 2020: $52.63 · 2021: $165 · 2022: $150 · 2023: $308 · 2024: $415 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Consulting Fee: $100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.18 |
| Consulting Fee | $100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $1,395.03 | 2019 | |
| Alcon Vision LLC | $699.58 | 2019-2025 | Tryptyr, Precision7, Air Optix |
| Johnson & Johnson Vision Care, INC. | $633.52 | 2019-2024 | Acuvue |
| Coopervision INC. | $489.35 | 2019-2023 | Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $358.36 | 2024-2025 | Infuse, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $234.75 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $144.90 | 2023 | Syfovre |
| Shire North American Group INC | $106.68 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $59.95 | 2024-2025 | Xdemvy |
| Lombart Brothers, INC. | $52.63 | 2020 | |
| Harrow Eye, LLC | $28.11 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $21.36 | 2019 | |
| Allergan, INC. | $20.24 | 2021 | |
| Dompe US, INC. | $19.40 | 2025 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $17.64 | 2019 | |
| Abbvie INC. | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.